Triple-negative breast cancer lacks effective targeted therapies, posing a significant clinical challenge and unmet medical need. HH0146, a first-in-class humanized CD24 mAb developed in Taiwan, holds a Taiwan invention patent and has completed PCT filing. It specifically activates macrophages, promoting cancer cell phagocytosis and reshaping the tumor immune microenvironment. As a novel immune checkpoint inhibitor, HH0146 demonstrates exceptional anti-tumor efficacy.

HH0146, a humanized CD24 monoclonal antibody, potently activates macrophage phagocytosis by 10-fold, reversing the immunosuppressive tumor microenvironment as a next-generation immune checkpoint therapy. It effectively inhibits TNBC distant metastasis and PDX tumor growth, extending mouse survival. HH0146 demonstrates superior anti-tumor efficacy, outperforming competing antibodies by 2-fold.

HH0146, a first-in-class humanized CD24 mAb for triple-negative breast cancer, targets a global market projected to reach $1.5 billion by 2030 (10% CAGR). Its CD24-positive applicability extends to 14 solid cancers, including pancreatic and liver cancer. HH0146 will collaborate with CDMO partners for GMP production to accelerate IND applications. Plans include entering the U.S., China, and EU markets, attracting investment, and advancing Taiwan’s biotech industry.